Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages

  Kanda, T ^a   Imazeki, F ^a   Yonemitsu, Y ^a   Mikami, S ^b   Takada, N ^c   Nishino, T ^d   Takashi, M ^e   Tsubota, A ^f   Kato, K ^g   Sugiura, N ^h   Tawada, A ^a   Wu, S ^a   Tanaka, T ^a   Nakamoto, S ^a   Mikata, R ^a   Tada, M ^a   Chiba, T ^a   Kurihara, T ^a   Arai, M ^a   Fujiwara, K ^a   Kanai, F ^a   Yokosuka, O ^a   more..

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kikkoman Hospital   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^d Tokyo Women s Medical University   (Japan)

^e Saiseikai Narashino Hospital   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NARITA RED CROSS HOSPITAL   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION CHIBA MEDICAL CENTER   (Japan)

Author keywords

antiviral treatment; chronic hepatitis C; TaqMan PCR; virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; COBAS TAQMAN HEPATITIS C VIRUS TEST; DRUG RESPONSE; DRUG WITHDRAWAL; EARLY VIRUS RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOCYTE COUNT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RAPID VIRUS RESPONSE; SUSTAINED VIRUS RESPONSE; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VIRUS DETECTION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, MESSENGER; RNA, VIRAL; TREATMENT OUTCOME;

EID: 79959574864     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01409.x     Document Type: Article

References (18)

1. Di Bisceglie AM,. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 3 (Suppl. 1): 34S-38S. (Pubitemid 27388069)
2. Ahmed A, Keeffe EB,. Hepatitis C virus and liver transplantation. Clin Liver Dis 2001; 5 (4): 1073-1090. (Pubitemid 33001021)
3. Hoofnagle JH, Seeff LB,. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355 (23): 2444-2451. (Pubitemid 44903748)
4. Kanda T, Imazeki F, Yokosuka O,. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4 (3): 548-561.
5. Kawai S, Yokosuka O, Kanda T, Imazeki F, Maru Y, Saisho H,. Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay. J Med Virol 1999; 58 (2): 121-126. (Pubitemid 29226853)
6. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341 (8859): 1501-1504. (Pubitemid 23168644)
7. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
8. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK,. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14 (10): 721-729. (Pubitemid 47414932)
9. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44 (6): 1617-1625. (Pubitemid 44953667)
10. Germer JJ, Harmsen WS, Mandrekar JN, Mitchell PS, Yao JD,. Evaluation of the COBAS TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J Clin Microbiol 2005; 43 (1): 293-298. (Pubitemid 40096314)
11. Matsuura K, Tanaka Y, Hasegawa I, et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol 2009; 47 (2): 385-389.
12. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123 (4): 1061-1069.
13. Lagging M, Wejstal R, Uhnoo I, et al. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009; 41 (6-7): 389-402.
14. Nakamoto S, Kanda T, Yonemitsu Y, et al. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 2009; 44 (7): 872-877.
15. Bacon BR, McHutchison JG,. Into the light: strategies for battling hepatitis C. Am J Manag Care 2007; 13 (Suppl. 12): S319-S326.
16. Korn K, Weissbrich B, Henke-Gendo C, et al. Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 2009; 47 (4): 1238-1240.
17. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465 (7294): 96-100.
18. Sarrazin C, Shiffman ML, Hadziyannis SJ, et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 2010; 52 (6): 832-838.